The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs

Biochemistry

Volumn 45, Issue 9, 2006, Pages 3040-3050

  McClendon, A Kathleen ^a   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG THERAPY; ENZYMES; GEOMETRY; INTERCALATION COMPOUNDS; NATURAL SCIENCES COMPUTING; SUBSTRATES;

CAMPTOTHECIN; CLEAVAGE COMPLEXES; ENZYME RESPONSE TO ANTICANCER DRUGS; ENZYME-DNA COMPLEX; SUPERCOILED DNA; TOPOISOMERASE-MEDIATED DNA CLEAVAGE; TRACKING SYSTEMS;

DNA;

6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CP 115953; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DNA TOPOISOMERASE (ATP HYDROLYSING) BETA; ETOPOSIDE; GENISTEIN; TOP 53; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CLEAVAGE; DNA PROTEIN COMPLEX; DNA STRAND BREAKAGE; DNA SUPERCOILING; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GEOMETRY; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA, SUPERHELICAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; HUMANS; INTERCALATING AGENTS; PLASMIDS; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; TIME FACTORS;

EID: 33644671059     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi051987q     Document Type: Article

References (82)

1. Osheroff, N. (1998) DNA topoisomerases, Biochim. Biophys. Acta 1400, 1-2.
2. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim. Biophys. Acta 1400, 63-81.
3. Wang, J. C. (1996) DNA topoisomerases, Annu. Rev. Biochem. 65, 635-692.
4. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice, Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253.
5. Champoux, J. J. (2001) DNA topisomerases: Structure, function, and mechanism, Annu. Rev. Biochem. 70, 369-413.
6. Wang, J. C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective, Nat. Rev. Mol. Cell Biol. 3, 430-440.
7. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes, Curr. Top. Med. Chem. 3, 1349-1364.
8. Sabourin, M., and Osheroff, N. (2002) Topoisomerases, in Wiley Encyclopedia of Molecular Medicine, pp 3192-3197, John Wiley & Sons, Inc., New York.
9. Velez-Cruz, R., and Osheroff, N. (2004) DNA topoisomerases: Type II, in Encyclopedia of Biological Chemistry, pp 806-811, Elsevier Inc., Amsterdam.
10. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D. (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme, Biochim. Biophys. Acta 1400, 83-106.
11. Wang, J. C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: The story of a simple molecular machine, Q. Rev. Biophys. 31, 107-144.
12. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta 1400, 173-184.
13. Hande, K. R. (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor, Eur. J. Cancer 34, 1514-1521.
14. Takimoto, C. H., Wright, J., and Arbuck, S. G. (1998) Clinical applications of the camptothecins, Biochim. Biophys. Acta 1400, 107-119.
15. Baldwin, E. L., and Osheroff, N. (2005) Etoposide, topoisomerase II and cancer, Curr. Med. Chem. Anti-Cancer Agents 5, 363-372.
16. Liu, L. F., and Miller, K. G. (1981) Eukaryotic DNA topoisomerases: Two forms of type I DNA topoisomerases from HeLa cell nuclei, Proc. Natl. Acad. Sci. U.S.A. 78, 3487-3491.
17. Halligan, B. D., Davis, J. L., Edwards, K. A., and Liu, L. F. (1982) Intra- and intermolecular strand transfer by HeLa DNA topoisomerase I, J. Biol. Chem. 257, 3995-4000.
18. Hanai, R., Caron, P. R., and Wang, J. C. (1996) Human TOP3: A single-copy gene encoding DNA topoisomerase III, Proc. Natl. Acad. Sci. U.S.A. 93, 3653-3657.
19. Goulaouic, H., Roulon, T., Flamand, O., Grondard, L., Lavelle, F., and Riou, J.-F. (1999) Purification and characterization of human DNA topoisomerase IIIα, Nucleic Acids Res. 27, 2443-2450.
20. Zunino, F., and Pratesi, G. (2004) Camptothecins in clinical development, Expert Opin. Invest. Drugs 13, 269-284.
21. Sriram, D., Yogeeswari, P., Thirumurugan, R., and Bal, T. R. (2005) Camptothecin and its analogues: A review on their chemotherapeutic potential, Nat. Prod. Res. 19, 393-412.
22. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., Crooke, S. T., et al. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme, J. Biol. Chem. 262, 16739-16747.
23. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II, Biochemistry 28, 8154-8160.
24. Heck, M. M., and Earnshaw, W. C. (1986) Topoisomerase II: A specific marker for cell proliferation, J. Cell Biol. 103, 2569-2581.
25. Hsiang, Y. H., Wu, H. Y., and Liu, L. F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells, Cancer Res. 48, 3230-3235.
26. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells, Cell Growth Differ. 2, 209-214.
27. Bauman, M. E., Holden, J. A., Brown, K. A., Harker, W. G., and Perkins, S. L. (1997) Differential immunohistochemical staining for DNA topoisomerase IIα and β in human tissues and for DNA topoisomerase IIβ in non-Hodgkin's lymphomas, Mod. Pathol. 10, 168-175.
28. Grue, P., Grasser, A., Sehested, M., Jensen, P. B., Uhse, A., Straub, T., Ness, W., and Boege, F. (1998) Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells, J. Biol. Chem. 273, 33660-33666.
29. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ, BioEssays 20, 215-226.
30. Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Physiological regulation of eukaryotic topoisomerase II, Biochim. Biophys. Acta 1400, 121-137.
31. Yang, X., Li, W., Prescott, E. D., Burden, S. J., and Wang, J. C. (2000) DNA topoisomerase IIβ and neural development, Science 287, 131-134.
32. Li, T. K., and Liu, L. F. (2001) Tumor cell death induced by topoisomerase-targeting drugs, Annu. Rev. Pharmacol. Toxicol. 41, 53-77.
33. Baguley, B. C., Leteurtre, F., Riou, J. F., Finlay, G. J., and Pommier, Y. (1997) A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine, Eur. J. Cancer 33, 272-279.
34. Moreland, N., Finlay, G. J., Dragunow, M., Holdaway, K. M., and Baguley, B. C. (1997) Cellular responses to methyl-N-[4-(9-acridinylamino)-2- methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells, Eur. J. Cancer 33, 1668-1676.
35. Gatto, B., and Leo, E. (2003) Drugs acting on the β isoform of human topoisomerase II (p180), Curr. Med. Chem. Anti-Cancer Agents 3, 173-185.
36. Sehested, M., Holm, B., and Jensen, P. B. (1996) Dexrazoxane for protection against cardiotoxic effects of anthracyclines, J. Clin. Oncol. 14, 2884.
37. Liu, L. F., and D'Arpa, P. (1992) Topoisomerase-targeting antitumor drugs: Mechanisms of cytotoxicity and resistance, Important Adv. Oncol., 79-89.
38. Baguley, B. C., and Ferguson, L. R. (1998) Mutagenic properties of topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 213-222.
39. Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: More questions than answers, Biochim. Biophys. Acta 1400, 195-211.
40. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 233-255.
41. Cozzarelli, N. R., and Wang, J. C. (1990) DNA Topology and Its Biological Effects, Cold Spring Harbor Laboratory Press, Plainview, NY.
42. Kanaar, R., and Cozzarelli, N. R. (1992) Roles of supercoiled DNA structure in DNA transactions, Curr. Opin. Struct. Biol. 2, 369-379.
43. Schvartzman, J. B., and Stasiak, A. (2004) A topological view of the replicon, EMBO Rep. 5, 256-261.
44. Liu, L. F., and Wang, J. C. (1987) Supercoiling of the DNA template during transcription, Proc. Natl. Acad. Sci. U.S.A. 84, 7024-7027.
45. Wu, H. Y., Shyy, S. H., Wang, J. C., and Liu, L. F. (1988) Transcription generates positively and negatively supercoiled domains in the template, Cell 53, 433-440.
46. Peter, B. J., Ullsperger, C., Hiasa, H., Marians, K. J., and Cozzarelli, N. R. (1998) The structure of supercoiled intermediates in DNA replication, Cell 94, 819-827.
47. Postow, L., Crisona, N. J., Peter, B. J., Hardy, C. D., and Cozzarelli, N. R. (2001) Topological challenges to DNA replication: Conformations at the fork, Proc. Natl. Acad. Sci. U.S.A. 98, 8219-8226.
48. Worland, S. T., and Wang, J. C. (1989) Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae, J. Biol. Chem. 264, 4412-4416.
49. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints, Biochemistry 36, 5934-5939.
50. Rodriguez, A. C. (2002) Studies of a positive supercoiling machine. Nucleotide hydrolysis and a multifunctional "latch" in the mechanism of reverse gyrase, J. Biol. Chem. 277, 29865-29873.
51. McClendon, A. K., Rodriguez, A. C., and Osheroff, N. (2005) Human topoisomerase IIα rapidly relaxes positively supercoiled DNA: Implications for enzyme action ahead of replication forks, J. Biol. Chem. 280, 39337-39345.
52. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage, J. Biol. Chem. 273, 17643-17650.
53. O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents, Biochemistry 41, 7989-7997.
54. Baldwin, E. L., Byl, J. A., and Osheroff, N. (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells, Biochemistry 43, 728-735.
55. Kingma, P. S., and Osheroff, N. (1997) Apurinic sites are position-specific topoisomerase II-poisons, J. Biol. Chem. 272, 1148-1155.
56. Ross, W., Rowe, T., Glisson, B., Yalowich, J., and Liu, L. (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage, Cancer Res. 44, 5857-5860.
57. Osheroff, N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide, Biochemistry 28, 6157-6160.
58. Robinson, M. J., and Osheroff, N. (1991) Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II, Biochemistry 30, 1807-1813.
59. Burden, D. A., Kingma, P. S., Froelich-Ammon, S. J., Bjornsti, M.-A., Patchan, M. W., Thompson, R. B., and Osheroff, N. (1996) Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes, J. Biol. Chem. 271, 29238-29244.
60. Chow, K. C., Macdonald, T. L., and Ross, W. E. (1988) DNA binding by epipodophyllotoxins and N-acyl anthracyclines: Implications for mechanism of topoisomerase II inhibition, Mol. Phamacol. 34, 467-473.
61. Utsugi, T., Shibata, J., Sugimoto, Y., Aoyagi, K., Wierzba, K., Kobunai, T., Terada, T., Oh-hara, T., Tsuruo, T., and Yamada, Y. (1996) Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer, Cancer Res. 56, 2809-2814.
62. Byl, J. A., Cline, S. D., Utsugi, T., Kobunai, T., Yamada, Y., and Osheroff, N. (2001) DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action, Biochemistry 40, 712-718.
63. Barnes, S., Peterson, T. G., and Coward, L. (1995) Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer, J. Cell. Biochem. 22 (Suppl.), 181-187.
64. Stoll, B. A. (1997) Eating to beat breast cancer: Potential role for soy supplements, Ann. Oncol. 8, 223-225.
65. Lamartiniere, C. A. (2000) Protection against breast cancer with genistein: A component of soy, Am. J. Clin. Nutr. 71, 1705S-1709S.
66. Robinson, M. J., Martin, B. A., Gootz, T. D., McGuirk, P. R., Moynihan, M., Sutcliffe, J. A., and Osheroff, N. (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage, J. Biol. Chem. 266, 14585-14592.
67. Spitzner, J. R., Chung, I. K., Gootz, T. D., McGuirk, P. R., and Muller, M. T. (1995) Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements, Mol. Pharmacol. 48, 238-249.
68. Bromberg, K. D., Burgin, A. B., and Osheroff, N. (2003) Quinolone action against human topoisomerase IIα: Stimulation of enzyme-mediated double-stranded DNA cleavage, Biochemistry 42, 3393-3398.
69. Elsea, S. H., McGuirk, P. R., Gootz, T. D., Moynihan, M., and Osheroff, N. (1993) Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: Correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential, Antimicrob. Agents Chemother. 37, 2179-2186.
70. Utsugi, T., Aoyagi, K., Asao, T., Okazaki, S., Aoyagi, Y., Sano, M., Wierzba, K., and Yamada, Y. (1997) Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II, Jpn. J. Cancer Res. 88, 992-1002.
71. Byl, J. A. W., Fortune, J. M., Burden, D. A., Nitiss, J. L., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: Primary cellular target and DNA cleavage enhancement, Biochemistry 38, 15573-15579.
72. Fortune, J. M., Velea, L., Graves, D. E., and Osheroff, N. (1999) DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition, Biochemistry 38, 15580-15586.
73. Nelson, E. M., Tewey, K. M., and Liu, L. F. (1984) Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methanesulfon-m-anisidide, Proc. Natl. Acad. Sci. U.S.A. 81, 1361-1365.
74. Pommier, Y., Minford, J. K., Schwartz, R. E., Zwelling, L. A., and Kohn, K. W. (1985) Effects of the DNA intercalators 4′-(9-acridinylamino) methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage, Biochemistry 24, 6410-6416.
75. Beck, W. T., Danks, M. K., Wolverton, J. S., Kim, R., and Chen, M. (1993) Drug resistance associated with altered DNA topoisomerase II, Adv. Enzyme Regul. 33, 113-127.
76. Vassetzky, Y. S., Alghisi, G. C., and Gasser, S. M. (1995) DNA topoisomerase II mutations and resistance to anti-tumor drugs, BioEssays 17, 767-774.
77. Kingma, P. S., Burden, D. A., and Osheroff, N. (1999) Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance, Biochemistry 38, 3457-3461.
78. Leroy, D., Kajava, A. V., Frei, C., and Gasser, S. M. (2001) Analysis of etoposide binding to subdomains of human DNA topoisomerase IIα in the absence of DNA, Biochemistry 40, 1624-1634.
79. Pommier, Y., and Marchand, C. (2005) Interfacial inhibitors of protein-nucleic acid interactions, Curr. Med. Chem. Anti-Cancer Agents 5, 421-429.
80. Waring, M. (1970) Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalation, J. Mol. Biol. 54, 247-279.
81. Waring, M. J. (1970) Drugs and DNA: Uncoiling of the DNA double helix as evidence of intercalation, Humangenetik 9, 234-236.
82. Wall, M. E., and Wani, M. C. (1995) Camptothecin and taxol: Discovery to clinic-Thirteenth Bruce F. Cain Memorial Award Lecture, Cancer Res. 55, 753-760.